177 related articles for article (PubMed ID: 33254286)
1. Reporting and interpretation of subgroup analyses in heart failure randomized controlled trials.
Khan MS; Khan MAA; Irfan S; Siddiqi TJ; Greene SJ; Anker SD; Sreenivasan J; Friede T; Tahhan AS; Vaduganathan M; Fonarow GC; Butler J
ESC Heart Fail; 2021 Feb; 8(1):26-36. PubMed ID: 33254286
[TBL] [Abstract][Full Text] [Related]
2. Credibility of claims of subgroup effects in randomised controlled trials: systematic review.
Sun X; Briel M; Busse JW; You JJ; Akl EA; Mejza F; Bala MM; Bassler D; Mertz D; Diaz-Granados N; Vandvik PO; Malaga G; Srinathan SK; Dahm P; Johnston BC; Alonso-Coello P; Hassouneh B; Walter SD; Heels-Ansdell D; Bhatnagar N; Altman DG; Guyatt GH
BMJ; 2012 Mar; 344():e1553. PubMed ID: 22422832
[TBL] [Abstract][Full Text] [Related]
3. Exercise-based cardiac rehabilitation for chronic heart failure: the EXTRAMATCH II individual participant data meta-analysis.
Taylor RS; Walker S; Ciani O; Warren F; Smart NA; Piepoli M; Davos CH
Health Technol Assess; 2019 May; 23(25):1-98. PubMed ID: 31140973
[TBL] [Abstract][Full Text] [Related]
4. A systematic review reveals that the credibility of subgroup claims in low back pain trials was low.
Saragiotto BT; Maher CG; Moseley AM; Yamato TP; Koes BW; Sun X; Hancock MJ
J Clin Epidemiol; 2016 Nov; 79():3-9. PubMed ID: 27297201
[TBL] [Abstract][Full Text] [Related]
5. Subgroup Analyses in Reporting of Phase III Clinical Trials in Solid Tumors.
Zhang S; Liang F; Li W; Hu X
J Clin Oncol; 2015 May; 33(15):1697-702. PubMed ID: 25897150
[TBL] [Abstract][Full Text] [Related]
6. Subgroup analyses in therapeutic cardiovascular clinical trials: are most of them misleading?
Hernández AV; Boersma E; Murray GD; Habbema JD; Steyerberg EW
Am Heart J; 2006 Feb; 151(2):257-64. PubMed ID: 16442886
[TBL] [Abstract][Full Text] [Related]
7. Subgroup Analysis of Trials Is Rarely Easy (SATIRE): a study protocol for a systematic review to characterize the analysis, reporting, and claim of subgroup effects in randomized trials.
Sun X; Briel M; Busse JW; Akl EA; You JJ; Mejza F; Bala M; Diaz-Granados N; Bassler D; Mertz D; Srinathan SK; Vandvik PO; Malaga G; Alshurafa M; Dahm P; Alonso-Coello P; Heels-Ansdell DM; Bhatnagar N; Johnston BC; Wang L; Walter SD; Altman DG; Guyatt GH
Trials; 2009 Nov; 10():101. PubMed ID: 19900273
[TBL] [Abstract][Full Text] [Related]
8. A meta-epidemiological study of subgroup analyses in cochrane systematic reviews of atrial fibrillation.
Paquette M; Alotaibi AM; Nieuwlaat R; Santesso N; Mbuagbaw L
Syst Rev; 2019 Oct; 8(1):241. PubMed ID: 31653275
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Evidence of Statistical Support and Corroboration of Subgroup Claims in Randomized Clinical Trials.
Wallach JD; Sullivan PG; Trepanowski JF; Sainani KL; Steyerberg EW; Ioannidis JP
JAMA Intern Med; 2017 Apr; 177(4):554-560. PubMed ID: 28192563
[TBL] [Abstract][Full Text] [Related]
10. Subgroup analysis in haematologic malignancies phase III clinical trials: A systematic review.
Báez-Gutiérrez N; Rodríguez-Ramallo H; Flores-Moreno S; Abdel-Kader Martín L
Br J Clin Pharmacol; 2021 Jul; 87(7):2635-2644. PubMed ID: 33270263
[TBL] [Abstract][Full Text] [Related]
11. No improvement in the reporting of clinical trial subgroup effects in high-impact general medical journals.
Gabler NB; Duan N; Raneses E; Suttner L; Ciarametaro M; Cooney E; Dubois RW; Halpern SD; Kravitz RL
Trials; 2016 Jul; 17(1):320. PubMed ID: 27423688
[TBL] [Abstract][Full Text] [Related]
12. Consolidated standards of reporting trials (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs) published in medical journals.
Turner L; Shamseer L; Altman DG; Weeks L; Peters J; Kober T; Dias S; Schulz KF; Plint AC; Moher D
Cochrane Database Syst Rev; 2012 Nov; 11(11):MR000030. PubMed ID: 23152285
[TBL] [Abstract][Full Text] [Related]
13. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
14. Subgroup Analysis in Pulmonary Hypertension-Specific Therapy Clinical Trials: A Systematic Review.
Rodríguez-Ramallo H; Báez-Gutiérrez N; Otero-Candelera R; Martín LA
J Pers Med; 2022 May; 12(6):. PubMed ID: 35743648
[TBL] [Abstract][Full Text] [Related]
15. Subgroup analyses in venous thromboembolism trials reporting pharmacological interventions: A systematic review.
Rodríguez-Ramallo H; Báez-Gutiérrez N; Abdel-Kader-Martín L; Otero-Candelera R
Thromb Res; 2023 Dec; 232():151-159. PubMed ID: 36266098
[TBL] [Abstract][Full Text] [Related]
16. Subgroup analysis and covariate adjustment in randomized clinical trials of traumatic brain injury: a systematic review.
Hernández AV; Steyerberg EW; Taylor GS; Marmarou A; Habbema JD; Maas AI
Neurosurgery; 2005 Dec; 57(6):1244-53; discussion 1244-53. PubMed ID: 16331173
[TBL] [Abstract][Full Text] [Related]
17. Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives.
Brookes ST; Whitley E; Peters TJ; Mulheran PA; Egger M; Davey Smith G
Health Technol Assess; 2001; 5(33):1-56. PubMed ID: 11701102
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Sex-Specific Reporting in Heart Failure Clinical Trials: Trial Flow and Results.
Au M; Whitelaw S; Khan MS; Mamas MA; Mbuagbaw L; Mulvagh SL; Voors AA; Van Spall HGC
JACC Adv; 2022 Oct; 1(4):100079. PubMed ID: 38939721
[TBL] [Abstract][Full Text] [Related]
19. Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020.
Sherry AD; Hahn AW; McCaw ZR; Abi Jaoude J; Kouzy R; Lin TA; Minsky B; Fuller CD; Meirson T; Msaouel P; Ludmir EB
JAMA Netw Open; 2024 Mar; 7(3):e243379. PubMed ID: 38546648
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
